These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20663272)

  • 1. DNA methylation profiling in cancer.
    Kondo Y; Issa JP
    Expert Rev Mol Med; 2010 Jul; 12():e23. PubMed ID: 20663272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dormant hypermethylated tumour suppressor genes: questions and answers.
    Esteller M
    J Pathol; 2005 Jan; 205(2):172-80. PubMed ID: 15643671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of epigenetic alterations in human thoracic malignancies: epigenetic alterations in lung cancer.
    Shinjo K; Kondo Y
    Methods Mol Biol; 2012; 863():221-39. PubMed ID: 22359296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
    Esteller M
    Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide profiling of promoter methylation in human.
    Hatada I; Fukasawa M; Kimura M; Morita S; Yamada K; Yoshikawa T; Yamanaka S; Endo C; Sakurada A; Sato M; Kondo T; Horii A; Ushijima T; Sasaki H
    Oncogene; 2006 May; 25(21):3059-64. PubMed ID: 16407832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells.
    Gebhard C; Benner C; Ehrich M; Schwarzfischer L; Schilling E; Klug M; Dietmaier W; Thiede C; Holler E; Andreesen R; Rehli M
    Cancer Res; 2010 Feb; 70(4):1398-407. PubMed ID: 20145141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epigenetics of oral cancer.
    Shaw R
    Int J Oral Maxillofac Surg; 2006 Feb; 35(2):101-8. PubMed ID: 16154320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
    Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
    Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis.
    Clark SJ
    Hum Mol Genet; 2007 Apr; 16 Spec No 1():R88-95. PubMed ID: 17613553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene silencing by DNA methylation in haematological malignancies.
    Boultwood J; Wainscoat JS
    Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA hypermethylation: when tumour suppressor genes go silent.
    Garinis GA; Patrinos GP; Spanakis NE; Menounos PG
    Hum Genet; 2002 Aug; 111(2):115-27. PubMed ID: 12189484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome.
    Suzuki H; Toyota M; Kondo Y; Shinomura Y
    Methods Mol Biol; 2009; 512():55-69. PubMed ID: 19347273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation, imprinting and cancer.
    Plass C; Soloway PD
    Eur J Hum Genet; 2002 Jan; 10(1):6-16. PubMed ID: 11896451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG islands: their potential as biomarkers for cancer.
    Shi H; Wang MX; Caldwell CW
    Expert Rev Mol Diagn; 2007 Sep; 7(5):519-31. PubMed ID: 17892361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA motifs associated with aberrant CpG island methylation.
    Feltus FA; Lee EK; Costello JF; Plass C; Vertino PM
    Genomics; 2006 May; 87(5):572-9. PubMed ID: 16487676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status.
    Arai E; Kanai Y
    Epigenomics; 2010 Jun; 2(3):467-81. PubMed ID: 22121905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
    Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of DNA methylation markers for diagnosing cancer.
    Qureshi SA; Bashir MU; Yaqinuddin A
    Int J Surg; 2010; 8(3):194-8. PubMed ID: 20139036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours.
    Esteller M; Herman JG
    J Pathol; 2002 Jan; 196(1):1-7. PubMed ID: 11748635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.